Can Stem Cells Help With Neuropathy?

Stem cell therapy shows genuine promise for neuropathy, but the honest picture in 2025 is that most of the evidence comes from animal studies, with only a handful of human trials reporting meaningful results. A systematic review and meta-analysis of human studies in diabetic peripheral neuropathy found that stem cell treatment significantly improved both motor and sensory nerve conduction velocity, along with gains in sensory perception and clinical symptom scores.¹ Those results are encouraging, but the field is still far from a standard, FDA-approved stem cell treatment you can walk into a clinic and receive. Understanding why researchers are optimistic, what’s actually been shown, and what to watch out for requires looking at several layers of evidence.

Why Stem Cells Are a Plausible Treatment for Nerve Damage

Neuropathy involves damage to peripheral nerves, the long fibers that carry signals between your brain, spinal cord, and the rest of your body. That damage can come from sustained high blood sugar in diabetes, from toxic effects of chemotherapy drugs, from physical injury, or from autoimmune and inflammatory conditions. The symptoms are familiar to anyone who has dealt with neuropathy: numbness, tingling, burning pain, and sometimes loss of muscle control in the hands and feet. Current treatments mostly manage pain rather than reverse the underlying nerve damage, which is why researchers have turned to stem cells as a potential way to actually repair nerves rather than just mask symptoms.

Stem cells are attractive here because damaged peripheral nerves need several things to heal: growth-promoting signals, new support cells to rebuild the insulating sheath around nerve fibers, reduced inflammation, and restored blood supply to the nerve. Stem cells appear to contribute to all of these at once, which is unusual for a single therapy. The mechanisms are not hypothetical; they have been demonstrated repeatedly in lab and animal studies, even though translating that success to human patients remains an ongoing challenge.

How Stem Cells Support Nerve Repair

The most well-documented way stem cells help damaged nerves is by releasing a cocktail of growth-promoting proteins called neurotrophic factors. Neural stem cells, for instance, secrete nerve growth factor, brain-derived neurotrophic factor, glial cell-line-derived neurotrophic factor, and several others. These proteins promote axon regrowth, improve the insulating myelin coating around nerve fibers, and help recover both sensory and motor function.² Think of it as the stem cells setting up a chemical environment that tells nearby nerve tissue “grow here, rebuild here.”

A second major contribution is calming inflammation. Neuropathic pain is driven partly by an overactive inflammatory response around damaged nerves. Mesenchymal stem cells, one of the most commonly studied types, are immunosuppressive. In animal models of nerve injury, adipose-derived stem cells reduced pro-inflammatory markers like IL-1β and IL-6 while increasing the anti-inflammatory marker IL-10.³ Bone marrow mesenchymal stem cells have similarly been shown to inhibit neuroinflammation in the spinal cord, and silencing a specific anti-inflammatory protein they produce (TSG-6) reduced both their pain-relieving and anti-inflammatory effects.⁴

Stem cells also contribute to remyelination, the rebuilding of the protective sheath around nerve fibers that speeds up signal transmission. Researchers have coaxed stem cells derived from human pluripotent sources into Schwann cell precursors, the specialized cells that produce myelin in the peripheral nervous system. These lab-grown cells secreted key neurotrophic factors and successfully formed myelin segments around nerve fibers in culture.⁵ Adipose-derived stem cells have been guided toward Schwann-like cell behavior using specialized scaffold materials, promoting axon growth, remyelination, and functional recovery in animal experiments.⁶

Finally, damaged nerves need blood supply to heal. Stem cells promote the formation of new blood vessels around injured nerves by secreting angiogenic factors. This microvascular support is especially relevant in diabetic neuropathy, where poor circulation compounds the nerve damage caused by metabolic dysfunction.

What Human Trials Have Shown So Far

The strongest clinical evidence to date comes from diabetic peripheral neuropathy. A 2024 systematic review and meta-analysis pooled data from human studies and found that stem cell therapy produced a weighted mean improvement of 2.2 m/s in motor nerve conduction velocity and 1.9 m/s in sensory nerve conduction velocity.¹ Vibration perception threshold and clinical symptom scores also improved significantly. These numbers indicate that nerves were conducting signals faster and patients were perceiving sensation better after treatment.

Those results are encouraging, but they come with caveats. The trials included in that meta-analysis were generally small and varied in design. Some used bone marrow cells, others used mesenchymal stem cells, and the delivery methods, dosing, and follow-up periods differed. Earlier animal work showed that some of the benefits from mesenchymal stem cell transplantation in diabetic models, particularly improvements in motor nerve conduction velocity and increases in certain growth factors, lasted only about four weeks before fading.⁷ Whether repeated treatments or modified approaches can extend those benefits is still being worked out.

Chemotherapy-Induced Neuropathy

Chemotherapy-induced peripheral neuropathy is a different beast from diabetic neuropathy, though the symptoms overlap. Drugs like cisplatin and paclitaxel damage nerve fibers directly, and no approved treatment reverses that damage once it occurs. Mesenchymal stem cells have shown particular promise here in animal models. In one study, nasal administration of mesenchymal stem cells after cisplatin or paclitaxel treatment completely reversed signs of established neuropathy in mice, including mechanical sensitivity, spontaneous pain, and loss of nerve fibers in the paw. The resolution was linked to normalization of mitochondrial energy production in the sensory neurons of the spinal area.⁸

That nasal delivery route is interesting on its own: rather than injecting cells directly into a nerve or the bloodstream, the researchers administered them through the nose, and the cells still reached the nervous system and produced effects. Human trials in chemotherapy-induced neuropathy are still in early stages. Evidence from experimental studies suggests mesenchymal stem cells reduce oxidative stress, inflammation, and cell death while promoting axon regeneration, and some researchers have proposed combining stem cell therapy with conventional pharmacological agents to improve outcomes.⁹

Which Type of Stem Cell Works Best

Researchers have tested a surprisingly wide range of stem cell types for peripheral nerve repair: bone marrow mesenchymal stem cells, adipose-derived (fat tissue) stem cells, dental pulp stem cells, neural stem cells, induced pluripotent stem cells, and others. For many practical purposes, bone marrow and adipose-derived mesenchymal stem cells have been the workhorses. A direct head-to-head comparison found that both types enhanced sciatic nerve repair compared to a cell-free scaffold, and their beneficial effects on nerve regeneration were comparable with no statistically significant differences between them.¹⁰ This is reassuring because adipose-derived stem cells are easier to harvest (from a simple fat biopsy) than bone marrow cells, which require a more invasive aspiration procedure.

Induced pluripotent stem cells, which are adult cells reprogrammed back to a stem-like state, have shown exciting results in animal models of nerve gap injuries. Nerve conduits seeded with neurospheres from induced pluripotent stem cells boosted axon growth and improved motor and sensory function in mice, and a long-term follow-up study confirmed that the cells enhanced regeneration and myelination without forming tumors even 48 weeks after surgery.¹¹ In rats, nerve conduits coated with human induced pluripotent stem cell-derived neural progenitors led to significantly better motor recovery and higher axon counts than empty conduits, though still not quite matching the gold standard of nerve autografts.¹²

Dental pulp stem cells are a newer entrant. An animal meta-analysis found they had the strongest effects across multiple nerve parameters, and when used in a hydrogel scaffold to bridge a large nerve gap in rats, they achieved functional recovery comparable to a nerve autograft, with the regenerated nerve tissue traced back to direct differentiation of the transplanted dental pulp cells.¹³ The ease of collecting these cells from extracted wisdom teeth makes them an appealing option for future clinical use.

Exosomes and Cell-Free Approaches

One of the more intriguing developments is the shift toward using products derived from stem cells rather than the cells themselves. Exosomes are tiny membrane-bound vesicles that cells release, packed with proteins, RNA, and signaling molecules. Stem cell-derived exosomes can mediate axon regrowth, activate Schwann cells, stimulate blood vessel formation, and regulate inflammation.¹⁴ In other words, they deliver many of the same benefits as the stem cells that produced them, without requiring live cells to be transplanted.

A 2025 systematic review and meta-analysis of preclinical studies found that exosome therapy improved nerve conduction velocity, helped restore nerve fiber density, eased neuropathic pain (particularly thermal sensitivity), improved blood flow in the foot and sciatic nerve, and restored nerve fiber structural measures including fiber diameter, axon diameter, and myelin sheath thickness in diabetic animal models.¹⁵ The appeal of exosomes is practical: they can be manufactured, stored, and dosed more easily than living cells, and they avoid some safety concerns associated with cell transplantation, like the theoretical risk of uncontrolled cell growth.

How Delivery Method Matters

Where and how you put stem cells in the body turns out to be a critical variable, and it’s one that many commercial clinics gloss over. A case series reviewing stem cell treatments for peripheral nerve injuries highlighted the challenges: intravenous injection, which is what many commercial providers offer, makes it hard to assert that cells injected into the bloodstream meaningfully reach and repair specific damaged nerves. Intramuscular injection could potentially improve muscle fiber diameter in partially denervated muscle, but is unlikely to restore voluntary control after a proximal nerve injury. Injecting directly into a nerve (intraneural injection) risks causing additional axon damage and dangerous pressure buildup within the nerve.¹⁶

The most promising preclinical results have often used localized delivery methods: cells seeded onto bioengineered scaffolds that are surgically placed to bridge a nerve gap, or targeted injections near the site of damage. A silk fibroin-based scaffold loaded with bone marrow stem cells and implanted across a nerve gap in rats yielded nerve regeneration results close to those of an autologous nerve graft, which remains the clinical gold standard.¹⁷ The nasal delivery route that reversed chemotherapy-induced neuropathy in mice represents a different kind of targeted approach, exploiting the nose-to-brain pathway to get cells to the nervous system without surgery. The point is that delivery is not a detail; it may determine whether the therapy works at all.

The Unproven Clinic Problem

If you search for “stem cell therapy for neuropathy” online, you will find clinics offering treatments today, often at costs of several thousand dollars per session. This is where caution becomes essential. As of 2021, more than 1,480 U.S. businesses operating over 2,750 clinics were selling purported stem cell treatments that are not FDA-approved and lack convincing evidence of safety and effectiveness. That number had more than quadrupled in just five years.¹⁸

Many of these clinics use autologous treatments, taking cells from a patient’s own fat tissue or bone marrow and reinjecting them, sometimes intravenously, sometimes at the site of symptoms. While this might sound harmless, these procedures have not gone through the rigorous clinical trial process needed to demonstrate that they actually work for neuropathy. The cells may not survive the processing, may be injected in an unhelpful location, or may simply not do what the clinic claims. The difference between the carefully controlled animal studies and early human trials described above and what a storefront clinic offers is significant. If a provider cannot point to published trial data for their specific protocol, that’s a red flag.

Tracking Nerve Repair With Imaging

One practical challenge in stem cell therapy for nerve damage is knowing whether the treatment is actually working at a cellular level while the patient is still alive. Researchers have been developing MRI-based methods to track transplanted stem cells in real time. In one approach, neural stem cells were labeled with a gadolinium-based contrast agent before being grafted onto injured sciatic nerves in rabbits. MRI could track the distribution and migration of the labeled cells for up to ten days after transplantation, and the grafted nerves showed better functional recovery and improved regeneration compared to controls.¹⁹ Similar work using iron oxide nanoparticle-labeled adipose-derived stem cells has confirmed that MRI can noninvasively track stem cell fate after transplantation in peripheral nerve injury models.²⁰ These imaging techniques remain research tools for now, but they represent a necessary step toward clinical use: before doctors can prescribe stem cell treatments confidently, they need ways to verify that transplanted cells are going where they’re supposed to and doing what they’re supposed to do.

Why Diabetic and Chemotherapy Neuropathies Get the Most Attention

Peripheral neuropathy has dozens of causes, but diabetic and chemotherapy-induced forms dominate the stem cell research landscape for practical reasons. Both are extremely common, both involve well-understood damage pathways that stem cells can theoretically interrupt, and both lack treatments that reverse rather than merely slow the damage. Diabetic neuropathy is driven by metabolic disruption, chronic inflammation, and poor blood flow to nerves, all targets that stem cells address through their cocktail of secreted factors.²¹ Chemotherapy-induced neuropathy involves direct toxic damage to nerve cells and their mitochondria, which mesenchymal stem cells have shown the ability to counteract in animal models.

Other forms of neuropathy, including those caused by autoimmune conditions, alcohol, infections, or hereditary disorders, have received far less stem cell research. This doesn’t mean stem cells couldn’t help with those conditions, but it means there’s little evidence to point to either way. If your neuropathy is caused by something other than diabetes or chemotherapy, the existing research applies to you only indirectly. The biological mechanisms of nerve repair are shared across neuropathy types, but the underlying disease process differs, and treatments need to be validated for each context.

Scaffolds and Bioengineered Nerve Conduits

For neuropathy caused by physical nerve injury, where a section of nerve has been crushed or severed, stem cells are increasingly being combined with bioengineered scaffolds. The idea is straightforward: a nerve gap needs a physical bridge, and seeding that bridge with stem cells gives the regrowing nerve fibers a supportive environment as they cross the gap. Researchers have tested conduits made from silk fibroin, biodegradable polymers, hydrogels, and composite membranes, all loaded with various stem cell types.

Cells derived from human induced pluripotent stem cells, transplanted via a silicone tube to bridge a nerve gap in mice, promoted axon regrowth and remyelination and achieved motor recovery comparable to a nerve autograft.²² That comparison to autografts matters because nerve autografts, where a less important nerve from elsewhere in the patient’s body is harvested and used to bridge the gap, are the current gold standard but come with the cost of sacrificing a donor nerve and creating a second surgical site. If stem cell-seeded conduits can match that standard, they could replace autografts entirely for certain injuries.

What a Realistic Timeline Looks Like

For someone living with neuropathy today, the practical question is when stem cell therapy might become a routine clinical option. The honest answer is that it remains years away from broad regulatory approval for neuropathy in most countries. The field is at the stage of refining cell types, delivery methods, dosing, and timing through a mix of late-stage animal studies and early-phase human trials. The exosome approach could potentially reach clinical use sooner than whole-cell therapy because it sidesteps some manufacturing and safety hurdles, but even that pathway is likely measured in years rather than months.

In the meantime, clinical trials are actively recruiting. If you have diabetic or chemotherapy-induced neuropathy and are interested in stem cell therapy, searching the ClinicalTrials.gov registry for current studies is a legitimate route. Enrolling in a trial gives you access to the therapy under medical supervision, with proper monitoring and follow-up, and you contribute data that will determine whether the therapy eventually becomes standard care. That’s a categorically different situation from paying out of pocket at a clinic selling an unproven product with no oversight and no outcome tracking.